Earnings

Novo Nordisk says any tussle with Sanofi's Toujeo will come down to formulary access

Novo Nordisk says any tussle with Sanofi's Toujeo will come down to formulary access

By

The Danish drugmaker said it expects an FDA decision about long-acting—and long-delayed—insulin Tresiba in October.

Merck's Keytruda gains market share in Q2

Merck's Keytruda gains market share in Q2

By

The immuno-oncology drug is competing with Bristol-Myers Squibb's Opdivo.

J&J prepares to defend Remicade market share

J&J prepares to defend Remicade market share

By

Johnson & Johnson CEO Alex Gorsky said physicians are unlikely to switch the majority of patients to a biosimilar version of Remicade.

Weight-loss drug prescriptions rise ... slowly

Weight-loss drug prescriptions rise ... slowly

By

First-quarter results show prescription weight-loss drugs continue to struggle with market and mind share.

Myriad expands companion diagnostic deals

Myriad expands companion diagnostic deals

By

The company partnered with AstraZeneca and BioMarin to identify which patients respond to experimental cancer drugs.

Five things for pharma marketers to know: Friday, May 1

Five things for pharma marketers to know: Friday, May 1

By

Nexium tops the list of Medicare's spending on brand drugs; Gilead Sciences doubles its first-quarter profit; Pfizer reportedly wants to buy a rare-disease drug company

Bristol-Myers Squibb sales rise, led by Eliquis and Opdivo

Bristol-Myers Squibb sales rise, led by Eliquis and Opdivo

By

Newly approved Opdivo added $40 million to the quarter's product sales, which rose 8.9% compared to the year-earlier period.

Pfizer reports uptake for cancer-therapy Ibrance

Pfizer reports uptake for cancer-therapy Ibrance

By

Sales of the new cancer drug topped expectations since its February launch.

Lilly sees sales fall but reaffirms 2015 revenue guidance

Lilly sees sales fall but reaffirms 2015 revenue guidance

By

First-quarter sales fell 1% but the drugmaker expects 2015 to be a growth year.

Five things for pharma marketers to know: Thursday, April 23

Five things for pharma marketers to know: Thursday, April 23

By

Novo Nordisk's Saxenda to cost $1,000 a month; Boehringer Ingelheim's drug receives priority review; AbbVie's hep.-C treatment Viekira Pak generates $231 million in first-quarter sales

Sales rise as Amgen outlines cardiovascular strategy

Sales rise as Amgen outlines cardiovascular strategy

By

Established products fueled at 12% jump in first-quarter sales.

Omnicom reports boost in Q1 net income

The holding company said pharma and health made up 11% of revenues during the first three months of the year.

J&J reports quarterly boost in drug sales

J&J reports quarterly boost in drug sales

By

The company reported $7.7 billion in pharma revenue in the first quarter despite a drop in overall sales and profit.

Lilly expands Trulicity marketing push, lowers 2015 guidance

Lilly expands Trulicity marketing push, lowers 2015 guidance

By

The drugmaker says its Trulicity focus now includes primary care doctors in addition to specialists, and that foreign exchange will take a bite out of 2015 performance.

Amgen, Novartis, BMS map future

Amgen, Novartis, BMS map future

By

Amgen execs assert there is still a future for 15-year-old Enbrel, Novartis sees off-label Avastin use pinch Lucentis sales and BMS has expanded its field force in anticipation of an Opdivo push.

Pfizer quarter and year sales slip, CEO indicates M&A not pressing

Pfizer quarter and year sales slip, CEO indicates M&A not pressing

By

CEO Ian Read told investors the company has cash to make a deal, but there is no urgent need.

J&J Q4 sales slip, but year finishes up 4.2%

J&J Q4 sales slip, but year finishes up 4.2%

By

Despite growth, some disappointment lurks in the numbers -- possibly for hepatitis C medication Olysio.

AstraZeneca Q3 sales rise, expects harsh 2015

AstraZeneca Q3 sales rise, expects harsh 2015

By

The company raised guidance for the end of the year and said Ranbaxy's being bounced from the Nexium competition probably means it has esomeprazole market to itself through 2014.

Lilly sales fall, drugmaker to keep rep count low

Lilly sales fall, drugmaker to keep rep count low

By

Cymbalta and Evista patent losses drove down sales, but Lilly said it does not plan to replenish the sales force it thinned in anticipation of the decline.

GSK restructures, as respiratory disappoints

GSK restructures, as respiratory disappoints

By

GlaxoSmithKline's third-quarter sales fell 10% for the quarter, compared to last year, and new Ellipta products failed to cushion the 24% drop in US Advair sales.

Hep. C medication boosts J&J earnings

Hep. C medication boosts J&J earnings

By

Hepatitis C medication Olysio contributed to the the 18% bump in Johnson & Johnson's third-quarter sales, but Gilead's new drug may diminish J&J's potential.

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

By

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

Amgen Q2 sales rise, company to lay off up to 2,900

Amgen Q2 sales rise, company to lay off up to 2,900

By

The majority of the layoffs will be in the US.

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

By

Patent losses and lost co-promotion agreements put a dent in sales.

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

By

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on horizon

By

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

By

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

By

Executives urge analysts to focus on the company's long-term potential.

J&J logs $19.5B in Q2 sales

J&J logs $19.5B in Q2 sales

By

Hepatitis C medication Olysio was a star, but the company cautions competition is coming.

Aegerion shows rare disease not slam dunk

Aegerion shows rare disease not slam dunk

By

Analyst reaction to this week's quarterly news reflected a need to woo investors, adding to some negative carryover from the previous year.


Email Newsletters


Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.